Literature DB >> 16789731

Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy.

Yipin Lu1, Zaneta Nikolovska-Coleska, Xueliang Fang, Wei Gao, Sanjeev Shangary, Su Qiu, Dongguang Qin, Shaomeng Wang.   

Abstract

An integrated, virtual database screening strategy has led to 7-[anilino(phenyl)methyl]-2-methyl-8-quinolinol (4, NSC 66811) as a novel inhibitor of the murine double minute 2 (MDM2)-p53 interaction. This quinolinol binds to MDM2 with a Ki of 120 nM and activates p53 in cancer cells with a mechanism of action consistent with targeting the MDM2-p53 interaction. It mimics three p53 residues critical in the binding to MDM2 and represents a promising new class of non-peptide inhibitors of the MDM2-p53 interaction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16789731     DOI: 10.1021/jm060023+

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  32 in total

Review 1.  Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach.

Authors:  I M Kapetanovic
Journal:  Chem Biol Interact       Date:  2006-12-16       Impact factor: 5.192

Review 2.  From laptop to benchtop to bedside: structure-based drug design on protein targets.

Authors:  Lu Chen; John K Morrow; Hoang T Tran; Sharangdhar S Phatak; Lei Du-Cuny; Shuxing Zhang
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 3.  Targeting the p53 pathway.

Authors:  Vita M Golubovskaya; William G Cance
Journal:  Surg Oncol Clin N Am       Date:  2013-07-30       Impact factor: 3.495

4.  High-performance liquid chromatographic enantioseparation of Betti base analogs on a newly developed isopropyl carbamate-cyclofructan6-based chiral stationary phase.

Authors:  Anita Aranyi; István Ilisz; Zoltán Pataj; István Szatmári; Ferenc Fülöp; Daniel W Armstrong; Antal Péter
Journal:  Chirality       Date:  2011-06-16       Impact factor: 2.437

5.  Ligand binding mode prediction by docking: mdm2/mdmx inhibitors as a case study.

Authors:  Nagakumar Bharatham; Kavitha Bharatham; Anang A Shelat; Donald Bashford
Journal:  J Chem Inf Model       Date:  2014-01-21       Impact factor: 4.956

Review 6.  Translational approaches targeting the p53 pathway for anti-cancer therapy.

Authors:  Frank Essmann; Klaus Schulze-Osthoff
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

Review 7.  Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Authors:  Mark Wade; Geoffrey M Wahl
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

8.  Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.

Authors:  Shanghai Yu; Dongguang Qin; Sanjeev Shangary; Jianyong Chen; Guoping Wang; Ke Ding; Donna McEachern; Su Qiu; Zaneta Nikolovska-Coleska; Rebecca Miller; Sanmao Kang; Dajun Yang; Shaomeng Wang
Journal:  J Med Chem       Date:  2009-12-24       Impact factor: 7.446

9.  A regioselective multicomponent protocol for the synthesis of novel bioactive 4-hydroxyquinolin-2(1H)-one grafted monospiropyrrolidine and thiapyrrolizidine hybrids.

Authors:  Mathan Sankaran; Chokkalingam Uvarani; Kumarasamy Chandraprakash; Swathi U Lekshmi; Sengupta Suparna; James Platts; Palathurai Subramaniam Mohan
Journal:  Mol Divers       Date:  2014-01-14       Impact factor: 2.943

10.  A novel binding pocket of cyclin-dependent kinase 2.

Authors:  Hao Chen; Rachel Van Duyne; Naigong Zhang; Fatah Kashanchi; Chen Zeng
Journal:  Proteins       Date:  2009-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.